News Gilead trumpets data with newly-bought magrolimab in blood c... Just three months after acquiring Forty Seven for $4.9 billion, Gilead has reported positive data on magrolimab, the lead drug from the deal, at ASCO 2020.
Views & Analysis Surviving COVID-19 as a bone marrow transplant patient Jayne Snell is one of the 1.5 million people in the UK to receive a letter asking them to stay at home for three months in a bid to avoid COVID-19.
News Gilead to buy immuno-oncology firm Forty Seven for $4.9bn Gilead is to buy immuno-oncology firm Forty Seven for $4.9 billion, adding an antibody targeting several blood cancers to its research pipeline.
Oncology In pursuit of a cure for cancer: An ASCO 2025 discussion wit... Dr Danny Nguyen, medical oncologist and haematologist at the City of Hope Orange County, spoke with pharmaphorum at ASCO 2025.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face